No retraction, correction or concern found when last checked on Oct 17, 2026.

Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)

Gabrielle S. Dijksteel, Magda M. W. Ulrich, Esther Middelkoop and 1 more

Frontiers in Microbiology · 2021 · Review

doi:10.3389/fmicb.2021.616979

Abstract

Antimicrobial peptides (AMPs) or host defense peptides protect the host against various pathogens such as yeast, fungi, viruses and bacteria. AMPs also display immunomodulatory properties ranging from the modulation of inflammatory responses to the promotion of wound healing. More interestingly, AMPs cause cell disruption through non-specific interactions with the membrane surface of pathogens. This is most likely responsible for the low or limited emergence of bacterial resistance against many AMPs. Despite the increasing number of antibiotic-resistant bacteria and the potency of novel AMPs to combat such pathogens, only a few AMPs are in clinical use. Therefore, the current review describes (i) the potential of AMPs as alternatives to antibiotics, (ii) the challenges toward clinical implementation of AMPs and (iii) strategies to improve the success rate of AMPs in clinical trials, emphasizing the lessons we could learn from these trials.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Antibiotic resistance is a global concern in health care as (new) resistance mechanisms are emerging and spreading globally. Resistant bacterial strains have been identified for various antibiotics in clinical use. For example, shortly after the emergence of penicillin-resistant Staphylococcus aureus in 1940, several pathogenic bacteria became resistant not only to penicillin but also to semi-synthetic penicillin, cephalosporins and newer carbapenems. In addition, the decline in the approval of new antibiotics by regulatory bodies has further exacerbated this problem.

2As alternatives to antibiotics, AMPs have been at the forefront of international efforts because they are less likely to induce bacterial resistance. AMPs are a diverse group of naturally occurring peptides of the innate defense system with activity against various pathogens such as yeast, fungi, viruses and bacteria. To inactivate these pathogens, AMPs display a multi-hit, non-specific and rapid action, resulting in the slow or limited emergence of resistance. Additionally, some AMPs show synergistic interactions with conventional antibiotics, which could decrease the selection of antibiotic resistant bacteria.

3Around the same time as the discovery of the first antibiotic penicillin in 1928, the first AMP nisin was discovered in milk. This AMP was approved by the FDA of the United States as a food preservative in 1988 due to its heat stability and tolerance of low pH. After the discovery of nisin, several other AMPs such as gramicidin, tyrocidine, alamethicin, purothionin, and defensins were isolated from bacteria, fungi, plants, invertebrates and vertebrates. However, the clinical application of AMPs as antimicrobials was limited due to toxicity considerations and other problems, such as high production costs as compared to antibiotics.

4The renewed interest in AMPs as a consequence of the increasing number of antibiotic resistant and tolerant bacteria has resulted in the FDA approval of gramicidin and polymyxin B as constituents in Neosporin® in 1955, colistin (polymyxin E) in 1962 and daptomycin in 2003. Several naturally occurring and synthetic AMPs have been clinically investigated to combat pathogenic bacteria but since the approval of daptomycin no new AMPs have been approved as antimicrobials. To understand this innovation gap, we reviewed the literature to describe the potential of AMPs as alternative to antibiotics and the challenges toward clinical application of AMPs. Additionally, we provide an overview of the strategies that are currently available to facilitate the successful clinical implementation of AMPs using examples from clinical trials.

Physiological Role of AMPs in the Skin

5The skin is not only a physical barrier to the external environment. It is an active immune organ protecting the host from harmful toxins and pathogenic organisms. The immune response of the skin involves various resident cells in the epidermis such as keratinocytes, melanocytes, Langerhans cells and γδ T cells, and in the dermis such as dendritic cells, macrophages, fibroblasts, mast cells, B and T cells, plasma cells and natural killer cells. These skin cells release several pro-inflammatory cytokines such as IL-17 and IL-22 and produce AMPs, which act as the first line of defense against microorganisms (Figure 1). AMPs display a broad-spectrum of antimicrobial activity against yeast, fungi, viruses and bacteria. For example, the human cathelicidin LL-37 shows activity against various Gram-positive and Gram-negative bacteria, and antibiotic-resistant bacterial strains. The same AMP also shows activity against fungi and some viruses such as influenza and HIV. showed that LL-37 inhibits HIV-1 replication and suggested that this AMP contributes to the protection against HIV-1 infection. Furthermore, reported that LL-37 inhibits Aspergillus fumigatus infection via direct antifungal activity and reduction of excessive inflammation.

6The ability to modulate the immune responses has been reported for several AMPs. LL-37 is a well-studied AMP with such immunomodulatory properties in humans. It acts as a chemoattractant for monocytes and promotes the production and release of various cytokines and chemokines that may direct the course and intensity of inflammation. Among others, LL-37 can reduce the inflammatory response via interaction with TLR. TLRs are widely expressed receptors on immune cells that recognize pathogenic-associated molecular patterns. LL-37 downregulates signaling through TLR4 by scavenging its ligand LPS as well as by disrupting the receptor complex function. Furthermore, LL-37 potentially elongates the lifespan of neutrophils via the suppression of neutrophil apoptosis, thereby enhancing host immunity. Additionally, report that LL-37 activates and promotes angiogenesis and migration of keratinocytes, which results in an improved re-epithelialization and granulation tissue formation.

7The antimicrobial and immunomodulatory effects of AMPs are necessary to maintain homeostasis of the skin function. Therefore, the production of AMPs is upregulated upon injury and infection. For example, in acne vulgaris several AMPs such as LL-37 and hBD-2 are upregulated by, e.g., keratinocytes in response to the Propionibacterium acnes. As the P. acnes strains vary in their ability to stimulate inflammatory responses, upregulation of AMPs could be beneficial due to their antimicrobial and anti-inflammatory effects. In some skin conditions, for example in diabetic foot ulcers, the upregulation of AMPs such as hBD-2, 3, and 4 is often not sufficient to control the inflammation and wound infection. Therefore, such skin conditions require specialized care for proper healing.

Structure and Mechanism of Action

8Antimicrobial peptides are usually small, consisting of 12–50 amino acids. They are composed of hydrophilic, hydrophobic and cationic residues (net charge +2 to +11). The cationicity and hydrophobicity of AMPs are critical for bactericidal activity. Together with the hydrophilic residues, the hydrophobic residues form an amphipathic structure for insertion into the bacterial membrane. To form this structure, some AMPs (i.e., α-helical peptides such as melittin) undergo conformational changes upon interaction with bacterial membranes, while others already have a rigid amphipathic structure (i.e., β-sheet peptides such as β-defensins) to target bacterial membranes. The positive charge of AMPs facilitates the initial binding of AMPs to the membrane surfaces via electrostatic interactions. Bacterial membranes consisting of negatively charged phospholipid headgroups such as phosphatidylglycerol, cardiolipin, or phosphatidylserine show high affinity for cationic AMPs. Contrarily, mammalian cell membranes that are enriched with zwitterionic phospholipids such as phosphatidylethanolamine, phosphatidylcholine, or sphingomyelin show low affinity for cationic AMPs due to their neutral net charge.

9Most AMPs cause membrane disruption through non-specific interactions with the membrane surface. They are suggested to form micelles or pores, causing loss of membrane integrity and consequently leakage of intracellular components, resulting in cell death. Depending on the membrane topology and geometry of pores, pores can be described by three models, i.e., barrel-stave, toroidal and sinking-raft model (Figure 2). In the sinking-raft model, AMPs lie on the membrane surface and cause an increase in membrane curvature. Self-aggregation of the peptide causes the AMPs to sink into the membrane, creating transient pores. In both the barrel-stave pore and toroidal pore, the peptide has a transmembrane topology. The main difference between these two models is that the formation of barrel-stave pores is driven by both hydrophobic and electrostatic interactions, whereas the formation of toroidal pores is mainly driven by electrostatic interactions. As a result, toroidal pores are covered by phosphate headgroups, initiating changes in membrane curvature. The mechanism of action of AMPs that form micelles is not well-understood. It is believed that these AMPs act by a detergent-like mechanisms causing intrinsic perturbations of the membrane.

10Membrane disruptive AMPs might also kill bacteria using non-membrane disruptive pathways, and vice versa. Additionally, they could act independently or in synergy with non-membrane disruptive AMPs. Non-membrane disruptive AMPs are able to transverse membranes to reach their intracellular target components. Such AMPs could inhibit protein-folding, proteases, cell division, the synthesis and metabolism of proteins, nucleic acids and cell walls. Previously, showed that two AMPs with clearly different structures, i.e., histatin 5 and human neutrophil (HNP)-1, act on similar pathways. The role of these AMPs suggests that membrane and non-membrane disruptive AMPs serve as equally important peptides of the innate defense system to inactivate pathogens.

Clinical Trials Using AMPs

11The results from pre-clinical studies using AMPs revealed that AMPs could be used for the prevention and treatment of various clinical conditions. For example, peptide coating of catheters using a novel peptide E6 prevented catheter associated infections in mouse models. PXL150 demonstrated efficacy against Pseudomonas aeruginosa in burn wounds in mouse models. Both LL-37 and IDR-1 restored pulmonary function in mice with pneumonia. Also, nisin demonstrated in vitro efficacy against Clostridium difficile. Furthermore, several AMPs including LL-37 displayed anti-biofilm activity in vivo. Based on promising pre-clinical results, numerous AMPs have been investigated in human clinical trials to demonstrate efficacy and safety. Several of these trials are still ongoing, others are completed, discontinued or approved. The successes and flaws of these clinically investigated AMPs are described in the following sections. Structural information, mechanism of action and the intended target of AMPs in clinical trials is provided in Table 1.

AMPs Approved for Clinical Use

12Currently, nisin, gramicidin, polymyxins, daptomycin and melittin are in clinical use as alternative to antibiotics because of their antimicrobial potency (Figure 3A). Nisin, also known as nisin A, is composed of 34 amino acids and consists of dehydrated, unsaturated and thioether amino acids, forming five lanthionine rings. It is naturally produced by lactic acid bacteria such as Lactococcus lactis and shows a broad-spectrum of bactericidal activity. L. lactis also produces nisin Z, F and Q, which differ by up to 10 amino acids from nisin A resulting in differences in physiochemical properties and antimicrobial activity. Among others, nisins inhibit cell wall synthesis through interactions with lipid II, a precursor molecule that is essential for bacterial cell-wall bio-synthesis. Nisins also form membrane pores causing cell lysis. Nisin A is approved as a food preservative and is GRAS. In clinical trials, the effect of nisin A has been investigated using probiotics, i.e., the consumption of live microorganisms (e.g., L. lactis) that produce nisin A. The results of a systematic review of such trials indicated that these probiotics reduce infectious complications and may subsequently reduce intensive care unit mortality. Minor but possible side effects of nisin A are itching (pruritus) and flushing of the skin, and nausea or vomiting. The safety profile together with the broad-spectrum of bactericidal activity, indicated that the application of nisin could extend beyond food-related bacteria. Applications of nisins in humans include dental-care and pharmaceutical products such as for the treatment of stomach ulcer and colon infections.

13Gramicidin or gramicidin D is a mixture of gramicidin A, B and C making up 80, 6, and 14% of the mixture, respectively. These AMPs are hydrophobic linear polypeptides composed of 15 amino acids. They are naturally produced by Gram-positive Brevibacillus brevis commonly found in soil. Gramicidins form ion-channels within the bacterial membrane, allowing the passive diffusion of Na+ and K+ along their concentration gradient. This results in membrane depolarization, osmotic swelling and lysis of bacterial cells. Gramicidin is effective against a variety of Gram-positive bacteria and is clinically used for ophthalmic purposes as a constituent in Neosporin®. In a clinical trial, patients suffering from hordeolum who received the ophthalmic solution containing gramicidin (Neosporin®) reported a comparable pain score as those who received a placebo treatment. Additionally, the duration of cure of these treatment groups was not statistically different (p = 0.988). The authors of this study suggested that the lack of statistically significant differences between the placebo and peptide-treated group could be due to the small sample size of 14 patients in each group. In another clinical study using a larger sample size of 91 patients, the effect of this ophthalmic solution on the duration of cure of bacterial-positive corneal ulcers was reported. An average of 12.5 days was required for complete re-epithelialization of these ulcers. This was more favorable compared to the duration of cure of ulcers treated with ofloxacin (13.7 days) and ciprofloxacin (14.4 days). These findings suggest that Neosporin® containing gramicidin could be used as an alternative to conventional antibiotics for such ophthalmic purposes. Another AMP in Neosporin® is polymyxin B.

14Polymyxins (A, B, C, D, and E) are a group of cyclic polypeptides naturally produced by Gram-positive Paenibacillus polymyxa. They show activity against MDR Gram-negative bacteria such as P. aeruginosa and Escherichia coli. Polymyxins bind to the lipid A component of LPS on the outer membrane of Gram-negative bacteria, which contributes to the insertion of the AMPs into the membrane. They can increase cell-permeability via a detergent-like mechanism, which causes cell death. Polymyxins in clinical use are polymyxin B and E, which differ only by one amino acid from each other. Polymyxin B is prescribed to treat eye infections, whereas polymyxin E is used to treat wound infections. These AMPs are recognized as crucial but last-resort treatment options because of their ability to induce adverse events. Nephrotoxicity and neurotoxicity are the most common adverse events reported for polymyxins. To optimize the clinical use of polymyxins without such severe adverse effects, clinical trials are currently being executed, e.g., in combination with different antimicrobial agents. Minor side effects, such as blurred vision, watery eyes, and sensitivity to light, have been reported for Neosporin® containing two AMPs, gramicidin and polymyxin B, and an aminoglycoside antibiotic neomycin. Thus, not one agent but the mixture of three antimicrobial agents are responsible for these minor side effects.

15Daptomycin is a cyclic lipopeptide consisting of 13 amino acids, which is naturally produced by the bacterium Streptomyces roseosporus. It shows bactericidal activity against Gram-positive bacteria, including antibiotic resistant strains. Daptomycin inhibits cell wall synthesis, causes membrane depolarization and forms membrane pores, eventually causing cell death. A daily treatment of 4-6 mg/kg daptomycin is recommended in critically ill patients. For the treatment of bacteria with reduced susceptibility high dosages of 10 mg/kg can be prescribed, which are also well tolerated. In a phase I clinical trial, 2 of 5 healthy volunteers who received 4 mg/kg per 12 h of daptomycin (8 mg/kg per day) developed reversible myopathy. Nonetheless, the number of incidence and the severity of myopathy were substantially decreased in healthy volunteers when the total dose of 8 mg/kg was administered once daily. Other studies reported that the development of myopathy was not related to the administration of daptomycin but to other factors such as concomitant medications, comorbidities and the number of surgical interventions. In a Phase IV clinical trial, the effect of daptomycin on the resolution of skin infections was compared to that of the standard of care, i.e., cloxacillin, nafcillin, oxacillin, flucloxacillin or vancomycin. The success rate of the daptomycin-treated patients was 71.5%, which was clinically and statistically comparable to the standard treatments with a success rate of 71.1%. In another clinical study, efficacy of daptomycin was demonstrated in a placebo-control trial. All patients also received a β-lactam therapy. In this study, the daptomycin treatment resulted in faster clearance of bacteremia than the control treatment (placebo + β-lactam therapy). Hence, combination therapy using daptomycin can improve the clinical success rate.

16Melittin is the predominant (40–48%) component of venom from the European honeybee Apis mellifera. It is composed of 26 amino acids and adopts an α-helical conformation upon interaction with the membrane surface. It possesses anti-inflammatory properties and is therefore approved by the FDA for relieving pain and swelling associated with rheumatoid arthritis, tendinitis, bursitis and multiple sclerosis. Melittin also forms membrane toroidal pores to inactivate pathogens. This was shown in several in vitro and animal experiments using cancer cells, viruses and (resistant) bacteria. Hence, similar to nisin, the clinical application of melittin could extend beyond the FDA-approved purposes. Side effects of melittin are redness and swelling of the skin at the side of administration, itching, trouble breathing, nausea, sleepiness and low blood pressure.

Flaws of Some AMPs

17Some clinical trials using AMPs were discontinued or terminated due to various reasons. For example, the Phase I clinical trial of friulimicin B in healthy volunteers was terminated due to its unfavorable pharmacokinetic profile. The nature of these unfavorable findings remains unknown and unexpected. Friulimicins (A, B, C, D, and E) are a group of naturally occurring peptides produced by Actinoplanes friuliensis and like daptomycin, they are cyclic lipopeptides (Figure 3B). Friulimicin B was clinically investigated and demonstrated efficacy in various murine infection models. It has similar physiochemical properties and mechanism of action as daptomycin but has been found to trigger different stress responses in Bacillus subtilis as compared to daptomycin. This might be related to differences in the pharmacokinetic profiles of these AMPs. Another AMP, Murepavadin (POL7080) failed unexpectedly in advanced clinical trials. Murepavadin is a 14 amino acid cyclic peptide that targets the LPS transport protein D (LptD) on the bacterial membrane to form pores. It was demonstrated to be safe in Phase I clinical trials in healthy volunteers and in subjects with an impaired renal function. Safety and efficacy of murepavadin were demonstrated in Phase II clinical trials in patients with acute exacerbation of non-cystic fibrosis bronchiectasis or ventilator-associated bacterial pneumonia due to P. aeruginosa. However, Phase III clinical trial of this AMP in patients with nosocomial pneumonia was prematurely ended due to higher than expected acute kidney injuries, i.e., 56% for the murepavadin plus ertapenem treated group versus 25–40% for the meropenem treated control group and according to the literature.

18Besides pharmacokinetic and safety issues, several AMPs have failed Phase III clinical trials because of lack of clear efficacy or lack of superiority over conventional treatments. A clear example is demonstrated for the AMP Neuprex® (rBPI21) which is a recombinant α-helical peptide consisting of the first 193 amino acids of the N-terminus of BPI. Clinical studies showed that patients with meningococcemia or hemorrhage due to trauma who received Neuprex® had no toxic side effects and showed a trend toward improved outcomes, i.e., reduced bone marrow aplasia and deaths. However, Neuprex® failed to show clear efficacy (p = 0.07) as compared to the placebo-treated group. Similar to Neuprex®, at least five AMP that have completed advanced clinical trials, failed to show clear efficacy (i.e., iseganan and XOMA-629) or superiority over conventional treatments (i.e., surotomycin, pexiganan, and omiganan). Nevertheless, the latter AMPs could be potential alternatives to conventional antibiotics due to their favorable safety profile and low or limited ability to induce bacterial resistance. Since antibiotics are no longer routinely used to treat bacterial infections as a consequence of resistance development, the ability of AMPs to induce bacterial resistance, is a more important parameter to consider during clinical trials. Hence, instead of superiority trials, equivalence or non-inferiority trials in which AMPs cause a similar effect as the standard treatment, should become more common. In two equivalence trials with systemic ofloxacin as the comparator, efficacy of topical pexiganan was determined in patients with diabetic foot ulcers. The combined results of these trials demonstrated that pexiganan was clinically comparable to this antibiotic. However, equivalence to ofloxacin was not acceptable as main evidence of efficacy and FDA approval of pexiganan. Additional clinical trials were required to demonstrate efficacy superior to a topical placebo cream plus standard treatment for diabetic foot ulcers. Of note, clinical trials are often not designed using placebo treatment only as control due to ethical reasons. In the additional trials, pexiganan plus standard treatment failed to meet the primary outcome, i.e., resolution of infection. Failure of AMPs in such trials may arise from stability issues, inappropriate drug administration or unknown interactions between the peptide and the standard treatment. Currently, the developers of pexiganan continue to evaluate the data to consider this peptide for the treatment of other clinical indications.

Challenges Toward Clinical Application of AMPs

19The development of AMPs for clinical use is accompanied by several challenges such as high development and production costs, cytotoxic issues, reduced activity in clinically relevant environments and the emergence of bacterial resistance, despite the initial claims that they may not induce resistance. To begin with, the manufacturing costs of antibiotics are relatively inexpensive. For example, aminoglycoside production costs $0.80 per gram as compared to $50–400 per gram of amino acid for AMPs by solid phase synthesis. As a consequence, alternative methods are required to promote commercial-scale production.

20Furthermore, AMPs acting on membranes are not completely selective to microbial cells and may be toxic for eukaryotic cells as well. Several AMPs cause hemolytic and/or cytotoxic effects at antimicrobial concentrations, limiting their wider utilization. Polymyxins are an example of such AMPs: they are crucial antimicrobials to eradicate MDR Gram-negative bacteria but they may cause nephrotoxicity and neurotoxicity at antimicrobial concentrations.

21Another drawback for the clinical implementation of AMPs is the low antimicrobial activity in clinically relevant environments. AMPs may lose their bactericidal activity under physiological salt conditions due to loss of electrostatic interactions between AMPs and cell membranes. In the presence of serum, AMPs may bind to proteins such as albumin. Additionally, AMPs can be susceptible to proteolytic degradation. Also, suggested that host cells can interfere with the activity of AMPs in a way similar to serum protein binding. This reduces the effective concentration of available AMPs to eradicate bacteria.

22Although AMPs do not seem to induce bacterial resistance, resistance to AMPs has been reported. AMPs that require specific recognition molecules such as LPS, Lipid A, Lipid I/II and LptD, on the membrane surface of bacteria most likely develop resistance. For example, resistance to nisin involves mutations in bacterial cells that induce changes in membrane and cell wall composition and eventually prevents the binding of nisin to lipid II. Alternatively, bacteria may inactivate nisin using dehydropeptide reductase, also known as nisinase. Resistance to polymyxins and cross-resistance to AMPs have also been reported. Resistance to polymyxins is mediated by the mrc-1 gene encoding a phosphoethanolamine modification in lipid A, which prevents the initial binding of polymyxins to the bacterial membranes. This gene was initially isolated from Chinese livestock animals and has been identified in the human fecal microbiome, indicating that polymyxin resistance is horizontally transferable. Moreover, reported that the aps AMP sensor/regulator system is important for S. aureus virulence in vivo. They show that AMPs may induce resistance mechanisms in MRSA via this system, which involves the D-alanylation of teichoic acids, the incorporation of lysophosphatidylglycerol in the bacterial membrane, the increase of lysine biosynthesis and AMP transport systems. Although the impact of bacterial resistance on the minimal inhibitory concentration of the AMPs (2–30-fold increase) is less dramatic than for antibiotics (100–1000-fold increase), the risk of bacterial resistance should be carefully investigated.

Improvement Strategies

23The majority of the AMPs under clinical evaluation are positively charged analogs of naturally occurring AMPs and are limited to topical or intravenous applications for an effective bio-available concentration of the peptides. Importantly, the route of drug administration could markedly affect the efficacy of AMPs as efficacy is dependent on the bio-distribution and stability of the peptides. Analogs of naturally occurring AMPs have been prepared to overcome the challenges associated with high production costs, low bio-availability and efficacy, and cytotoxic effects of AMPs (Figure 4). Strategies to improve the performance of AMPs are described in the following sections.

Ultra-Short and/or Truncated AMPs

24Efforts to reduce production costs include alternative peptide synthesis methods and the production of ultra-short and/or truncated AMPs. The latter has been pursued by several companies. The AMPs OP-145, P113, LTX-109, and EA-230 all consist of a lower number of amino acids as compared to their “original” peptide LL-37, histatin-5, bovine lactoferrin and loop-2 of β-hCG, respectively. Beside truncation of AMPs, the synthesis of ultra-short AMPs such as the 5-amino acid linear peptide SGX942 further reduces the production costs of AMPs. Alternatively, solution phase synthesis or by chemoenzymatic methods could be used for production of small AMPs. This remains challenging for large peptides and therefore a biotechnological approach is often considered, i.e., the production of AMPs in microorganisms. Magainin, hBD-3, melittin and other AMPs have been synthesized using calmodulin as carrier protein. This protein protects the producing bacterial cells, e.g., E. coli from the toxic effects of the AMPs and prevents degradation of the AMP during the production process. Alternative approaches to obtain AMPs from plants or bacterial ribosomes have been reviewed by, and, respectively.

Delivery Systems

25To improve the bio-availability of AMPs, delivery systems can be used to administer the peptides. Nisin is readily degraded by enzymes in the gastrointestinal tract. To target C. difficile, a bacterium that can infect the colon, nisin requires a delivery vehicle to reach the colon without being digested and absorbed by the upper gastrointestinal tract. To achieve this, nisin has been encapsulated in pectin/HPMC compression coated tablets to form an enzymatically controlled delivery system. Alternative systems such as liposomes, nanoparticles, and nisin-controlled gene expression in Lactobacillus gasseri have also shown to be successful delivery systems. Colon-specific delivery approaches such as pro-drugs and conjugates have been reviewed by and. These approaches have also been used to improve the in vivo bio-availability of different AMPs, for example Polymyxin E, which is administered as an inactive pro-drug that undergoes hydrolysis to release the active AMPs. Polymyxin E was also successfully integrated into hydrogels for the treatment of burn wound infections. Please note that such delivery systems, may not only improve the bio-availability of the AMPs but may also improve the efficacy and reduce cytotoxicity, as a consequence of increased solubility and specificity, respectively.

Chemical Modifications

26The order and position of amino acids were found to play an important role in the biological activity of the hLT-1-1 peptide, according to its structure-activity relationship. Also, the α-helical content, the hydrophobicity and amphipathicity of AMPs may affect their bactericidal activity and cytotoxicity. reported that an increase in the hydrophobicity might induce hemolytic activity of AMPs. Another group showed that a reduction in the net positive charge of AMPs may not affect the bactericidal efficacy of AMPs but may reduce cytotoxic effects. For higher bactericidal activity and less cytotoxic effects, the introduction of arginine was found to be superior to lysine for providing the positive charge of AMPs. To improve proteolytic stability, different approaches have been used such as the introduction of D-amino acids, cyclization, amidation or acetylation of the terminal regions. To increase the salt and serum stability of AMPs, tryptophan or β-naphthylalanine end-tagging of the terminal regions of AMPs could be considered.

Specifically Targeted AMPs (STAMPS)

27Due to the broad-spectrum activity and non-specific mechanisms of action of AMPs, these peptides may induce cytotoxic effects as well. To reduce these effects, STAMPS have been designed. STAMPS selectively target and kill a specific pathogenic species without affecting the normal flora. They consist of at least two regions, i.e., one or multiple targeting regions and a killing region linked by a spacer. The targeting region improves the activity of the AMPs by enhancing the initial binding of the peptide to the specific pathogenic determinants on the membrane. Using two are more targeting regions reduces the likelihood of bacterial resistance and improves efficacy. Currently, C16G2 which is a synthetic AMP or STAMP, is under clinical investigation for the treatment of tooth decay by Streptococcus mutans. The N-terminus of C16G2, is the targeting region for S. mutans and the C-terminus is the killing region or AMP G2. C16G2 demonstrated a strong safety profile and efficacy against S. mutans.

Combination Therapy

28To improve treatment outcomes, two or more antibiotics are often used in clinical practice. The same could be done for novel AMPs as many peptides show synergistic interactions with conventional antibiotics. This could not only reduce the amount of peptide needed for effective treatment and thus reduce costs but may also extend the lifetime of current antibiotics. There are numerous examples of AMPs demonstrating synergism. The combination of polymyxins with carbapenems or rifampicin suppresses the development of polymyxin resistance. Also, Polymyxin B is used in combination with gramicidin and neomycin in Neosporin® due to their synergistic interactions, resulting in reduced resistance development and less cytotoxic effects.

Counter-Ion Selection

29The final step of AMP synthesis, which involves the cleavage and deprotection of the peptide chain with, e.g., TFA should be investigated to improve efficacy and reduce cytotoxicity. Counter-ions such as TFA anions are able to interact with positively charged AMPs and affect the hydrogen-bonding network along with the secondary structure. Also, TFA was shown to be cytotoxic for mammalian cells. Previously, studied the effect of three counter-ions, i.e., TFA anions, acetate and chlorides, on the bactericidal efficacy and cytotoxicity of a set of AMPs. They found that the peptide salts of acetate and chlorides seemed to be more potent antimicrobials than trifluoroacetates. However, trifluoroacetates have greater ability to promote α-helix formation in, e.g., LL-37. Additionally, acetate counter-ions seemed to be associated with high hemolytic activity. In contrast, pexiganan acetate showed less cytotoxicity in cell viability assays and was the most stable salt for pexiganan. Hence, superiority of one salt over another is peptide-dependent and should be taken into account.

Conclusion and Perspectives

30As a result of the increasing number of antibiotic resistant bacteria, there has been a renewed interest in AMPs as a potential alternative to conventional antibiotics. AMPs display clear advantages over conventional antibiotics to combat various infectious diseases. In particular, (i) their broad spectrum of activity, (ii) multi-hit, non-specific and rapid mode of action, which results in limited emergence of resistance, (iii) the potential immunomodulatory properties and (iv) synergistic interactions with conventional antibiotics could eliminate the threat of MDR bacteria. Yet, until now, only a few AMPs (e.g., nisin, gramicidin, polymyxins, daptomycin, and melittin) have reached the clinic. Challenges toward clinical application of AMPs include cytotoxic effects, production costs, and problems related to peptide bio-availability and efficacy. To overcome these challenges, several strategies have been designed such as the preparation of ultra-short/truncated AMPs, delivery systems and STAMPS, chemical modifications and the careful selection of a counter-ion in the final step of AMP synthesis. Although not all AMPs in the clinical pipeline will reach the market, these strategies could improve the success rate of AMPs in clinical trials. Nonetheless, several AMPs in clinical trials have failed due to lack of clear efficacy or superiority over conventional antibiotics, while showing a trend toward improved clinical outcomes. Therefore, practical strategies should also be considered in future clinical testing of AMPs as we have learned the following lessons:

31The application of AMPs can extend beyond FDA-approved clinical indications;

32Defining the most optimal dose and administration regimen might reduce cytotoxic effects of AMPs;

33Efficacy of AMPs can be demonstrated in equivalence or non-inferiority trials with an antibiotic as comparator;

34Bacterial resistance development should be included as one of the primary outcome parameters in clinical trials of AMPs;

35The bio-availability and efficacy of AMPs can be improved using delivery systems and,

36The combination AMPs with conventional antibiotics or other compounds (e.g., AMPs) might result in an improved antimicrobial effect in clinical trials.

37Taking these lessons into consideration, an increasing number of AMPs could reach the market as multi-functional, potent and long-lasting antimicrobials against various infectious diseases.

Author Contributions

38GD wrote a draft version of the manuscript. MU, EM, and BB contributed to the design of the review and revised the manuscript. All authors assisted with the interpretation of the findings, read, and approved the final manuscript.

Conflict of Interest

39The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 204

1.
Abraham E. P. Chain E. (1940 ). An enzyme from bacteria able to destroy penicillin. Nature 146:837.
Not in our library10.1038/146837a0
2.
Agier J. Efenberger M. Brzezińska-Blaszczyk E. (2015 ). Cathelicidin impact on inflammatory cells. Cent. Eur. J. Immunol. 40 225–235.
Not in our library10.5114/ceji.2015.51359
3.
Alam M. Z. Wu X. Mascio C. Chesnel L. Hurdle J. G. (2015 ). Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob. Agents Chemother. 59 5165–5170.
Not in our library10.1128/aac.01087-15
4.
Alni R. H. Tavasoli F. Barati A. Badarbani S. S. Salimi Z. Babaeekhou L. (2020 ). Synergistic activity of melittin with mupirocin: a study against methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolates. Saudi J. Biol. Sci. 27, 2580–2585.
Not in our library10.1016/j.sjbs.2020.05.027
5.
Alves E. M. Heneine L. G. D. Pesquero J. L. de Merlo L. A. (2011 ). Pharmaceutical Composition Containin an Apitoxin Fraction and Use Thereof. Google Patents No: WO2011041865. International Research Report (Art. 21 (3)).
Not in our library
6.
Andersson D. I. Hughes D. Kubicek-Sutherland J. Z. (2016 ). Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist. Updat. 26 43–57.
Not in our library10.1016/j.drup.2016.04.002
7.
Arbeit R. D. Maki D. Tally F. P. Campanaro E. Eisenstein B. I. (2004 ). The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38 1673–1681.
Not in our library10.1086/420818
8.
Arcilla M. S. van Hattem J. M. Matamoros S. Melles D. C. Penders J. de Jong M. D. (2016 ). Dissemination of the mcr-1 colistin resistance gene. Lancet Infect. Dis. 16 147–149.
Not in our library10.1016/s1473-3099(15)00540-x
9.
Bacalum M. Radu M. (2015 ). Cationic antimicrobial peptides cytotoxicity on mammalian cells: an analysis using therapeutic index integrative concept. Int. J. Pept. Res. Ther. 21 47–55.
Not in our library10.1007/s10989-014-9430-z
10.
Antimicrobial Peptides · 2013
No notice
11.
Ball L. J. Goult C. M. Donarski J. A. Micklefield J. Ramesh V. (2004 ). NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org. Biomol. Chem. 2 1872–1878.
Not in our library10.1039/b402722a
12.
Bartoloni A. Mantella A. Goldstein B. P. Dei R. Benedetti M. Sbaragli S. (2004 ). In-vitro activity of nisin against clinical isolates of Clostridium difficile. J. Chemother. 16 119–121.
Not in our library10.1179/joc.2004.16.2.119
13.
Bastos M. D. C. D. F. Coelho M. L. V. Santos O. C. D. S. (2015 ). Resistance to bacteriocins produced by gram-positive bacteria. Microbiology 161 683–700.
Not in our library10.1099/mic.0.082289-0
14.
Batoni G. Maisetta G. Esin S. (2016 ). Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim. Biophys. Acta Biomembr. 1858 1044–1060.
Not in our library10.1016/j.bbamem.2015.10.013
15.
Beisswenger C. Bals R. (2005 ). Functions of antimicrobial peptides in host defense and immunity. Curr. Protein Pept. Sci. 6 255–264.
Not in our library10.2174/1389203054065428
16.
Benet L. Z. (1978 ). Effect of route of administration and distribution on drug action. J. Pharmacokinet. Biopharm. 6 559–585.
Not in our library10.1007/bf01062110
17.
Bergman P. Walter-Jallow L. Broliden K. Agerberth B. Soderlund J. (2007 ). The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr. HIV Res. 5 410–415.
Not in our library10.2174/157016207781023947
18.
Bertelsen K. Dorosz J. Hansen S. K. Nielsen N. C. Vosegaard T. (2012 ). Mechanisms of peptide-induced pore formation in lipid bilayers investigated by oriented 31P solid-state NMR spectroscopy. PLoS One 7:e47745.
Not in our library10.1371/journal.pone.0047745
19.
BioSpace (2019 ). Polyphor Temporarily Halts Enrollment in the Phase III Studies of Murepavadin for the Treatment of Patients with Nosocomial Pneumonia.
Not in our library
20.
Björn C. Noppa L. Näslund Salomonsson E. Johansson A. L. Nilsson E. Mahlapuu M. (2015 ). Efficacy and safety profile of the novel antimicrobial peptide PXL150 in a mouse model of infected burn wounds. Int. J. Antimicrob. Agents 45, 519–524.
Not in our library10.1016/j.ijantimicag.2014.12.015
21.
Blay G. Le Lacroix C. Zihler A. Fliss I. (2007 ). In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett. Appl. Microbiol. 45 252–257.
Not in our library10.1111/j.1472-765x.2007.02178.x
22.
Blondelle S. E. Ostresh J. M. Houghten R. A. Perez-Paya E. (1995 ). Induced conformational states of amphipathic peptides in aqueous/lipid environments. Biophys J. 68 351–359.
Not in our library10.1016/s0006-3495(95)80194-3
23.
Booth J. H. Benrimoj S. I. Nimmo G. R. (1994 ). In vitro interactions of neomycin sulfate, bacitracin, and polymyxin B sulfate. Int. J. Dermatol. 33 517–520.
Not in our library10.1111/j.1365-4362.1994.tb02872.x
24.
Bosscha M. I. Van Dissel J. T. Kuijper E. J. Swart W. Jager M. J. (2004 ). The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration. Br. J. Ophthalmol. 88 25–28.
Not in our library10.1136/bjo.88.1.25
25.
Boto A. De La Lastra J. M. P. González C. C. (2018 ). The road from host-defense peptides to a new generation of antimicrobial drugs. Molecules 23:311.
Not in our library10.3390/molecules23020311
26.
Bray B. L. (2003 ). Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2 587–593.
Not in our library10.1038/nrd1133
27.
Brogden K. A. (2005 ). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3 238–250.
Not in our library10.1038/nrmicro1098
28.
Brown K. L. Poon G. F. T. Birkenhead D. Pena O. M. Falsafi R. Dahlgren C. (2011 ). Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J. Immunol. 186 5497–5505.
Not in our library10.4049/jimmunol.1002508
29.
Bulger E. M. Maier R. V. Sperry J. Joshi M. Henry S. Moore F. A. (2014 ). A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 149 528–536.
Not in our library10.1001/jamasurg.2013.4841
30.
Carretero M. Escámez M. J. García M. Duarte B. Holguín A. Retamosa L. (2008 ). In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 128 223–236.
Not in our library10.1038/sj.jid.5701043
31.
Chan D. I. Prenner E. J. Vogel H. J. (2006 ). Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta Biomembr. 1758 1184–1202.
Not in our library10.1016/j.bbamem.2006.04.006
32.
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications · 2020
No notice
33.
Cheng M. P. Lawandi A. Butler-Laporte G. Paquette K. Lee T. C. (2018 ). Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. Trials 19 1–10.
Not in our library10.1186/s13063-018-2668-6
34.
Chennupati S. K. Chiu A. G. Tamashiro E. Banks C. A. Cohen M. B. Bleier B. S. (2009 ). Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am. J. Rhinol. Allergy 23 46–51.
Not in our library10.2500/ajra.2009.23.3261
35.
Choi J. H. Jang A. Y. Lin S. Lim S. Kim D. Park K. (2015 ). Melittin, a honeybee venom-derived antimicrobial peptide, may target methicillin-resistant Staphylococcus aureus. Mol. Med. Rep. 12 6483–6490.
Not in our library10.3892/mmr.2015.4275
36.
Chu H. L. Yu H. Y. Yip B. S. Chih Y. H. Liang C. W. Cheng H. T. (2013 ). Boosting salt resistance of short antimicrobial peptides. Antimicrob. Agents Chemother. 57 4050–4052.
Not in our library10.1128/aac.00252-13
37.
Cisneros J. M. Rosso-Fernández C. M. Roca-Oporto C. De Pascale G. Jiménez-Jorge S. Fernández-Hinojosa E. (2019 ). Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit. Care 23:383.
Not in our library10.1186/s13054-019-2627-y
38.
Cleveland J. Montville T. J. Nes I. F. Chikindas M. L. (2001 ). Bacteriocins: safe, natural antimicrobials for food preservation. Int. J. Food Microbiol. 71 1–20.
Not in our library10.1016/s0168-1605(01)00560-8
39.
Committee for Proprietary Medicinal Products (2001 ). Points to consider on switching between superiority and non-inferiority. Br. J. Clin. Pharmacol. 52:223.
Not in our library10.1046/j.0306-5251.2001.01397-3.x
40.
Cornish J. Callon K. E. Lin C. Q. X. Xiao C. L. Mulvey T. B. Cooper G. J. S. (1999 ). Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am. J. Physiol. Endocrinol. Metab. 277 E779–E783.
Not in our library10.1152/ajpendo.1999.277.5.e779
41.
Crowther G. S. Baines S. D. Todhunter S. L. Freeman J. Chilton C. H. Wilcox M. H. (2013 ). Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 68 168–176.
Not in our library10.1093/jac/dks359
42.
Csato M. Kenderessy A. S. Dobozy A. (1989 ). Enhancement of Candida albicans killing activity of separated human epidermal cells by α-melanocyte stimulating hormone. Br. J. Dermatol. 121 145–147.
Not in our library10.1111/j.1365-2133.1989.tb01415.x
43.
Gramicidin A: A New Mission for an Old Antibiotic · 2015
Not checked
44.
Dean S. N. Bishop B. M. van Hoek M. L. (2011 ). Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front. Microbiol. 2:128.
Not in our library10.3389/fmicb.2011.00128
45.
Delves-Broughton J. Blackburn P. Evans R. J. Hugenholtz J. (1996 ). Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek Int. J. Gen. Mol. Microbiol. 69 193–202.
Not in our library10.1007/bf00399424
46.
Demetriades D. Smith J. S. Jacobson L. E. Moncure M. Minei J. Nelson B. J. (1999 ). Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. J. Trauma Inj. Infect. Crit. Care 46 667–677.
Not in our library10.1097/00005373-199904000-00018
47.
Desai N. (2013 ). Stable Pexiganan Formulation. Google Patents No, WO/2013/188286. International Research Report (Art. 21 (3)).
Not in our library
48.
Di Nardo A. Braff M. H. Taylor K. R. Na C. Granstein R. D. McInturff J. E. (2007 ). Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 178 1829–1834.
Not in our library10.4049/jimmunol.178.3.1829
49.
Dobias J. Poirel L. Nordmann P. (2017 ). Cross-resistance to human cationic antimicrobial peptides and to polymyxins mediated by the plasmid-encoded MCR-1?. Clin. Microbiol. Infect. 23 676.e1–676.e5.
Not in our library10.1016/j.cmi.2017.03.015
50.
Doi K. Hu X. Yuen P. S. T. Leelahavanichkul A. Yasuda H. Kim S. M. (2008 ). AP214, an analogue of α-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int. 73 1266–1274.
Not in our library10.1038/ki.2008.97
51.
Dosler S. Karaaslan E. Alev Gerceker A. (2016 ). Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against gram-negative bacteria. J. Chemother. 28 95–103.
Not in our library10.1179/1973947815y.0000000004
52.
Dvorchik B. H. Brazier D. DeBruin M. F. Arbeit R. D. (2003 ). Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47 1318–1323.
Not in our library10.1128/aac.47.4.1318-1323.2003
53.
Easton D. M. Nijnik A. Mayer M. L. Hancock R. E. W. (2009 ). Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 27 582–590.
Not in our library10.1016/j.tibtech.2009.07.004
54.
Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging · 2014
No notice
55.
Eckert R. Brady K. M. Greenberg E. P. Qi F. Yarbrough D. K. He J. (2006 ). Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob. Agents Chemother. 50 3833–3838.
Not in our library10.1128/aac.00509-06
56.
Eckert R. Sullivan R. Shi W. (2012 ). Targeted antimicrobial treatment to re-establish a healthy microbial flora for long-term protection. Adv. Dent. Res. 24 94–97.
Not in our library10.1177/0022034512453725
57.
Edgerton M. Koshlukova S. E. Araujo M. W. B. Patel R. C. Dong J. Bruenn J. A. (2000 ). Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. Antimicrob. Agents Chemother. 44 3310–3316.
Not in our library10.1128/aac.44.12.3310-3316.2000
58.
Edsfeldt S. Holm B. Mahlapuu M. Reno C. Hart D. A. Wiig M. (2017 ). PXL01 in sodium hyaluronate results in increased PRG4 expression: a potential mechanism for anti-adhesion. Ups. J. Med. Sci. 122 28–34.
Not in our library10.1080/03009734.2016.1230157
59.
Endermann R. Vente A. Labischinski H. (2007 ). “Friulimicin B, a cyclic lipopeptide, exhibits potent efficacy in a murine pneumococcal pneumonia model,” in Poster Presentation at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago.
Not in our library
60.
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies · 2006
No notice
61.
Falagas M. E. Kasiakou S. K. Tsiodras S. Michalopoulos A. (2006 ). The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res. 4 138–146.
Not in our library10.3121/cmr.4.2.138
62.
Falanga A. Lombardi L. Franci G. Vitiello M. Iovene M. R. Morelli G. (2016 ). Marine antimicrobial peptides: nature provides templates for the design of novel compounds against pathogenic bacteria. Int. J. Mol. Sci. 17:785.
Not in our library10.3390/ijms17050785
63.
Fang Z. Wusgal L. Cheng H. Liang L. (2017 ). “Natural biodegradable medical polymers: therapeutic peptides and proteins,” in Science and Principles of Biodegradable and Bioresorbable Medical Polymers: Materials and Properties, ed. Zhang X. C. (Amsterdam: Elsevier Inc), 321–350.
Not in our library10.1016/b978-0-08-100372-5.00011-8
64.
Fry D. E. (2018 ). Antimicrobial peptides. Surg. Infect. 19 804–811.
Not in our library10.1089/sur.2018.194
65.
Fulco P. Wenzel R. P. (2006 ). Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti. Infect. Ther. 4 939–945.
Not in our library10.1586/14787210.4.6.939
66.
Gajski G. Garaj-Vrhovac V. (2013 ). Melittin: a lytic peptide with anticancer properties. Environ. Toxicol. Pharmacol. 36 697–705.
Not in our library10.1016/j.etap.2013.06.009
67.
Galar A. Muñoz P. Valerio M. Cercenado E. García-González X. Burillo A. (2019 ). Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution. Int. J. Antimicrob. Agents 53 40–48.
Not in our library10.1016/j.ijantimicag.2018.09.015
68.
Gaussier H. Morency H. Lavoie M. C. Subirade M. (2002 ). Replacement of trifluoroacetic acid with HCl in the hydrophobic purification steps of pediocin PA-1: a structural effect. Appl. Environ. Microbiol. 68 4803–4808.
Not in our library10.1128/aem.68.10.4803-4808.2002
69.
Genetic Engineering, and Biotechnology News (2016 ). Dipexium’s Diabet. Foot Ulcer Candidate Fail. Phase III Trials. Available online at: https://www.genengnews.com/news/dipexiums-diabetic-foot-ulcer-candidate-fails-phase-iii-trials/ (accessed September 30, 2020).
Not in our library
70.
Gentilucci L. De Marco R. Cerisoli L. (2010 ). Chemical modifications designed to improve peptide stability: incorporation of non-natural amino Acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16 3185–3203.
Not in our library10.2174/138161210793292555
71.
Giroir B. P. Scannon P. J. Levin M. (2001 ). Bactericidal/permeability-increasing protein—Lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit. Care Med. 29 S130–S135.
Not in our library10.1097/00003246-200107001-00039
72.
Gordon Y. J. Romanowski E. G. McDermott A. M. (2005 ). A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30 505–515.
Not in our library10.1080/02713680590968637
73.
Gottler L. M. Ramamoorthy A. (2009 ). Structure, membrane orientation, mechanism, and function of pexiganan—a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta Biomembr. 1788 1680–1686.
Not in our library10.1016/j.bbamem.2008.10.009
74.
Gualillo O. Lago F. Gómez-Reino J. Casanueva F. F. Dieguez C. (2003 ). Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett. 552 105–109.
Not in our library10.1016/s0014-5793(03)00965-7
75.
Guinan E. C. Barbon C. M. Kalish L. A. Parmar K. Kutok J. Mancuso C. J. (2011 ). Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci. Transl. Med. 3:110ra118.
Not in our library10.1126/scitranslmed.3003126
76.
Guo L. Mclean J. S. Yang Y. Eckert R. Kaplan C. W. Kyme P. (2015 ). Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc. Natl. Acad. Sci. U.S.A. 112 7569–7574.
Not in our library10.1073/pnas.1506207112
77.
Håkansson J. Ringstad L. Umerska A. Johansson J. Andersson T. Boge L. (2019 ). Characterization of the in vitro, ex vivo, and in vivo efficacy of the antimicrobial peptide DPK-060 used for topical treatment. Front. Cell. Infect. Microbiol. 9:174.
Not in our library10.3389/fcimb.2019.00174
78.
Hale J. D. F. Hancock R. E. W. (2007 ). Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti. Infect. Ther. 5 951–959.
Not in our library10.1586/14787210.5.6.951
79.
He J. Yarbrough D. K. Kreth J. Anderson M. H. Shi W. Eckert R. (2010 ). Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans. Antimicrob. Agents Chemother. 54 2143–2151.
Not in our library10.1128/aac.01391-09
80.
Heinemann B. Williams R. (1966 ). Inactivation of nisin by pancreatin. J. Dairy Sci. 49 312–314.
Not in our library10.3168/jds.s0022-0302(66)87854-2
81.
Hirunwiwatkul P. Wachirasereechai K. (2005 ). Effectiveness of combined antibiotic ophthalmic solution in the treatment of hordeolum after incision and curettage: a randomized, placebo-controlled trial: a pilot study. J. Med. Assoc. Thail. 88 647–650.
Not in our library
82.
Antimicrobial Peptide LL-37 and IDR-1 Ameliorate MRSA Pneumonia in Vivo · 2013
Not checked
83.
Ingham A. B. Moore R. J. (2007 ). Recombinant production of antimicrobial peptides in heterologous microbial systems. Biotechnol. Appl. Biochem. 47:207.
Not in our library10.1042/ba20060207
84.
Isaksson J. Brandsdal B. O. Engqvist M. Flaten G. E. Svendsen J. S. M. Stensen W. (2011 ). A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J. Med. Chem. 54 5786–5795.
Not in our library10.1021/jm200450h
85.
Ishida H. Nguyen L. T. Gopal R. Aizawa T. Vogel H. J. (2016 ). Overexpression of antimicrobial, anticancer, and transmembrane peptides in Escherichia coli through a calmodulin-peptide fusion system. J. Am. Chem. Soc. 138 11318–11326.
Not in our library10.1021/jacs.6b06781
86.
Itoh H. Tokumoto K. Kaji T. Paudel A. Panthee S. Hamamoto H. (2017 ). Total synthesis and biological mode of action of WAP-8294A2: a menaquinone-targeting antibiotic. J. Org. Chem. 83 6924–6935.
Not in our library10.1021/acs.joc.7b02318
87.
Jiang Z. Vasil A. I. Hale J. D. Hancock R. E. W. Vasil M. L. Hodges R. S. (2008 ). Effects of net charge and the number of positively charged residues on the biological activity of amphipathic α-helical cationic antimicrobial peptides. Biopolym. Pept. Sci. Sect. 90 369–383.
Not in our library10.1002/bip.20911
88.
Johansson J. Gudmundsson G. H. Rottenberg M. E. Berndt K. D. Agerberth B. (1998 ). Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273 3718–3724.
Not in our library10.1074/jbc.273.6.3718
89.
Jorgensen J. H. Crawford S. A. Kelly C. C. Patterson J. E. (2003 ). In vitro activity of daptomycin against vancomycin-resistant Enterococci of various van types and comparison of susceptibility testing methods. Antimicrob. Agents Chemother. 47 3760–3763.
Not in our library10.1128/aac.47.12.3760-3763.2003
90.
Kampshoff F. Willcox M. D. P. Dutta D. (2019 ). A pilot study of the synergy between two antimicrobial peptides and two common antibiotics. Antibiotics 8:60.
Not in our library10.3390/antibiotics8020060
91.
Kaplan C. W. Sim J. H. Shah K. R. Kolesnikova-Kaplan A. Shi W. Eckert R. (2011 ). Selective membrane disruption: mode of action of C16G2, a specifically targeted antimicrobial peptide. Antimicrob. Agents Chemother. 55 3446–3452.
Not in our library10.1128/aac.00342-11
92.
Khan I. Oh D. H. (2016 ). Integration of nisin into nanoparticles for application in foods. Innov. Food Sci. Emerg. Technol. 34 376–384.
Not in our library10.1016/j.ifset.2015.12.013
93.
Kim S. H. Nguyen T. H. Maynard H. D. (2017 ). Polymeric drug conjugates by controlled radical polymerization. Comprehens. Biomater. II 4 493–505.
Not in our library10.1016/b978-0-08-100691-7.00020-3
94.
Kramer N. E. Hasper H. E. van den Bogaard P. T. C. Morath S. de Kruijff B. Hartung T. (2008 ). Increased D-alanylation of lipoteichoic and a thickened septum are main determinants in the nisin resistance mechanism of Lactococcus lactis. Microbiology 154 1755–1762.
Not in our library10.1099/mic.0.2007/015412-0
95.
Kudrimoti M. Curtis A. Azawi S. Worden F. Katz S. Adkins D. (2016 ). Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled Phase 2a clinical study. J. Biotechnol. 239 115–125.
Not in our library10.1016/j.jbiotec.2016.10.010
96.
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study · 2010
No notice
97.
Kwa A. Kasiakou S. K. Tam V. H. Falagas M. E. (2007 ). Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev. Anti. Infect. Ther. 5 811–821.
Not in our library10.1586/14787210.5.5.811
98.
The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine Antigens · 2016
Not checked
99.
Larrick J. W. Hirata M. Balint R. F. Lee J. Zhong J. Wright S. C. (1995 ). Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 63 1291–1297.
Not in our library10.1128/iai.63.4.1291-1297.1995
100.
Laverty G. (2014 ). Cationic antimicrobial peptide cytotoxicity. SOJ Microbiol. Infect. Dis. 2:112.
Not in our library10.15226/sojmid.2013.00112
101.
Le C. F. Fang C. M. Sekaran S. D. (2017 ). Intracellular targeting mechanisms by antimicrobial peptides. Antimicrob. Agents Chemother. 61:e02340-16.
Not in our library10.1128/aac.02340-16
102.
Le Lay C. Dridi L. Bergeron M. G. Ouellette M. Fliss I. I. (2016 ). Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J Med Microbiol 65 169–175.
Not in our library10.1099/jmm.0.000202
103.
Anti-Inflammatory Applications of Melittin, a Major Component of Bee Venom: Detailed Mechanism of Action and Adverse Effects · 2016
No notice
104.
Leeds J. A. Sachdeva M. Mullin S. Dzink-Fox J. LaMarche M. J. (2012 ). Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob. Agents Chemother. 56 4463–4465.
Not in our library10.1128/aac.06354-11
105.
Lenhard J. R. Nation R. L. Tsuji B. T. (2016 ). Synergistic combinations of polymyxins. Int. J. Antimicrob. Agents 48 607–613.
Not in our library10.1016/j.ijantimicag.2016.09.014
106.
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design · 2017
No notice
107.
Li J. Nation R. L. (2006 ). Old polymyxins are back: is resistance close? Clin. Infect. Dis. 43 663–664.
Not in our library10.1086/506571
108.
Li J. Nation R. L. Milne R. W. Turnidge J. D. Coulthard K. (2005 ). Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int. J. Antimicrob. Agents 25 11–25.
Not in our library10.1016/j.ijantimicag.2004.10.001
109.
Li M. Cha D. J. Lai Y. Villaruz A. E. Sturdevant D. E. Otto M. (2007 ). The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66 1136–1147.
Not in our library10.1111/j.1365-2958.2007.05986.x
110.
Liang S. C. Tan X. Y. Luxenberg D. P. Karim R. Dunussi-Joannopoulos K. Collins M. (2006 ). Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203 2271–2279.
Not in our library10.1084/jem.20061308
111.
Lipsky B. A. Holroyd K. J. Zasloff M. (2008 ). Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47 1537–1545.
Not in our library10.1086/593185
112.
Liu Y.-Y. Wang Y. Walsh T. R. Yi L.-X. Zhang R. Spencer J. (2016 ). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16 161–168.
Not in our library10.1016/s1473-3099(15)00424-7
113.
LL37 Inhibits Aspergillus fumigatus Infection via Directly Binding to the Fungus and Preventing Excessive Inflammation · 2019
Not checked
114.
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents · 2016
No notice
115.
Malanovic N. Leber R. Schmuck M. Kriechbaum M. Cordfunke R. A. Drijfhout J. W. (2015 ). Phospholipid-driven differences determine the action of the synthetic antimicrobial peptide OP-145 on Gram-positive bacterial and mammalian membrane model systems. Biochim. Biophys. Acta Biomembr. 1848 2437–2447.
Not in our library10.1016/j.bbamem.2015.07.010
116.
Marr A. K. Gooderham W. J. Hancock R. E. (2006 ). Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6 468–472.
Not in our library10.1016/j.coph.2006.04.006
117.
Martin-Loeches I. Dale G. E. Torres A. (2018 ). Murepavadin: a new antibiotic class in the pipeline. Expert Rev. Anti. Infect. Ther. 16 259–268.
Not in our library10.1080/14787210.2018.1441024
118.
Matsuzaki K. (1999 ). Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta Biomembr. 1462 1–10.
Not in our library10.1016/s0005-2736(99)00197-2
119.
McCrudden M. T. C. McLean D. T. F. Zhou M. Shaw J. Linden G. J. Irwin C. R. (2014 ). The host defence peptide LL-37 is susceptible to proteolytic degradation by wound fluid isolated from foot ulcers of diabetic patients. Int. J. Pept. Res. Ther. 20 457–464.
Not in our library10.1007/s10989-014-9410-3
120.
Meikle T. G. Conn C. E. Separovic F. Drummond C. J. (2016 ). Exploring the structural relationship between encapsulated antimicrobial peptides and the bilayer membrane mimetic lipidic cubic phase: studies with gramicidin A′. RSC Adv. 6 68685–68694.
Not in our library10.1039/c6ra13658c
121.
Memariani H. Memariani M. Moravvej H. Shahidi-Dadras M. (2020 ). Melittin: a venom-derived peptide with promising anti-viral properties. Eur. J. Clin. Microbiol. Infect. Dis. 39 5–17.
Not in our library10.1007/s10096-019-03674-0
122.
Mensa B. Howell G. Scott R. DeGrado W. (2014 ). Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob. Agents Chemother. 58 5136–5145.
Not in our library10.1128/aac.02955-14
123.
Mercer D. K. Robertson J. C. Miller L. Stewart C. S. O’Neil D. A. (2020 ). NP213 (Novexatin®): a unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile. Med. Mycol. 58 1064–1072.
Not in our library10.1093/mmy/myaa015
124.
Midura-Nowaczek K. Markowska A. (2014 ). Antimicrobial peptides and their analogs: searching for new potential therapeutics. Perspect. Med. Chem. 6:PMC.S13215.
Not in our library10.4137/pmc.s13215
125.
Miller L. S. Sørensen O. E. Liu P. T. Jalian H. R. Eshtiaghpour D. Behmanesh B. E. (2005 ). TGF-α regulates TLR expression and function on epidermal keratinocytes. J. Immunol. 174 6137–6143.
Not in our library10.4049/jimmunol.174.10.6137
126.
Mishra B. Reiling S. Zarena D. Wang G. (2017 ). Host defense antimicrobial peptides as antibiotics: design and application strategies. Curr. Opin. Chem. Biol. 38 87–96.
Not in our library10.1016/j.cbpa.2017.03.014
127.
Mitra D. Yadav A. Prithyani S. John L. E. Rodrigues S. Shah R. (2019 ). The antiplaque efficacy of lantibiotic Nisin extract mouthrinse. J. Indian Soc. Periodontol. 23 31–34.
Not in our library10.4103/jisp.jisp_326_18
128.
Miyake O. Ochiai A. Hashimoto W. Murata K. (2004 ). Origin and diversity of alginate lyases of families PL-5 and -7 in Sphingomonas sp. strain A1. J. Bacteriol. 186 2891–2896.
Not in our library10.1128/jb.186.9.2891-2896.2004
129.
Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus · 2016
No notice
130.
Montesinos E. Bardají E. (2008 ). Synthetic antimicrobial peptides as agricultural pesticides for plant-disease control. Chem. Biodivers. 5 1225–1237.
Not in our library10.1002/cbdv.200890111
131.
Morrison D. C. Jacobs D. M. (1976 ). Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13 813–818.
Not in our library10.1016/0019-2791(76)90181-6
132.
Muchintala D. Suresh V. Raju D. Sashidhar R. B. (2020 ). Synthesis and characterization of cecropin peptide-based silver nanocomposites: its antibacterial activity and mode of action. Mater. Sci. Eng. C 110:110712.
Not in our library10.1016/j.msec.2020.110712
133.
Nagaoka I. Suzuki K. Niyonsaba F. Tamura H. Hirata M. (2012 ). Modulation of neutrophil apoptosis by antimicrobial peptides. ISRN Microbiol. 2012:345791.
Not in our library10.5402/2012/345791
134.
Nagy I. Pivarcsi A. Kis K. Koreck A. Bodai L. McDowell A. (2006 ). Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microb. Infect. 8 2195–2205.
Not in our library10.1016/j.micinf.2006.04.001
135.
Nell M. J. Tjabringa G. S. Wafelman A. R. Verrijk R. Hiemstra P. S. Drijfhout J. W. (2006 ). Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27 649–660.
Not in our library10.1016/j.peptides.2005.09.016
136.
Neu T. Henrich B. (2003 ). New thermosensitive delivery vector and its use to enable nisin-controlled gene expression in Lactobacillus gasseri. Appl. Environ. Microbiol. 69 1377–1382.
Not in our library10.1128/aem.69.3.1377-1382.2003
137.
Nibbering P. H. Ravensbergen E. Welling M. M. van Berkel L. A. van Berkel P. H. C. Pauwels E. K. J. (2001 ). Human lactoferrin and peptides derived from Its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. 69 1469–1476.
Not in our library10.1128/iai.69.3.1469-1476.2001
138.
Nordström R. Malmsten M. (2017 ). Delivery systems for antimicrobial peptides. Adv. Colloid Interf. Sci. 242 17–34.
Not in our library10.1016/j.cis.2017.01.005
139.
Oo T. Z. Cole N. Garthwaite L. Willcox M. D. P. Zhu H. (2010 ). Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. J. Antimicrob. Chemother. 65 1243–1251.
Not in our library10.1093/jac/dkq106
140.
Ooi N. Miller K. Hobbs J. Rhys-Williams W. Love W. Chopra I. (2009 ). XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J. Antimicrob. Chemother. 64 735–740.
Not in our library10.1093/jac/dkp299
141.
Orlov D. Hong T. Menzel L. P. Azimov R. Falla T. J. Waring A. J. (1805 ). “Bactericidal mechanism of iseganan (IB-367), a rapidly acting antimicrobial protegrin peptide,” in Proceedings of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago.
Not in our library
142.
Park S.-C. Kim J.-Y. Shin S.-O. Jeong C.-Y. Kim M.-H. Shin S. Y. (2006 ). Investigation of toroidal pore and oligomerization by melittin using transmission electron microscopy. Biochem. Biophys. Res. Commun. 343 222–228.
Not in our library10.1016/j.bbrc.2006.02.090
143.
Perona J. J. Craik C. S. (1997 ). Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J. Biol. Chem. 272 29987–29990.
Not in our library10.1074/jbc.272.48.29987
144.
Petrof E. O. Dhaliwal R. Manzanares W. Johnstone J. Cook D. Heyland D. K. (2012 ). Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit. Care Med. 40 3290–3302.
Not in our library10.1097/ccm.0b013e318260cc33
145.
Peyrusson F. Butler D. Tulkens P. M. Van Bambeke F. (2015 ). Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. Antimicrob. Agents Chemother. 59 5747–5760.
Not in our library10.1128/aac.00827-15
146.
Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds · 2018
No notice
147.
Phee L. M. Betts J. W. Bharathan B. Wareham D. W. (2015 ). Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob. Agents Chemother. 59 4544–4550.
Not in our library10.1128/aac.00753-15
148.
Piper C. Hill C. Cotter P. D. Ross R. P. (2011 ). Bioengineering of a nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q and Z. Microb. Biotechnol. 4 375–382.
Not in our library10.1111/j.1751-7915.2010.00207.x
149.
Prajna N. V. George C. Selvaraj S. Lu K. L. McDonnell P. J. Srinivasan M. (2001 ). Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea 20 175–178.
Not in our library10.1097/00003226-200103000-00013
150.
Prince A. Sandhu P. Kumar P. Dash E. Sharma S. Arakha M. (2016 ). Lipid-II independent antimicrobial mechanism of nisin depends on its crowding and degree of oligomerization. Sci. Rep. 6 1–15.
Not in our library10.1038/srep37908
151.
Rand K. H. Houck H. J. (2004 ). Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48 2871–2875.
Not in our library10.1128/aac.48.8.2871-2875.2004
152.
Rivas-Santiago B. Trujillo V. Montoya A. Gonzalez-Curiel I. Castañeda-Delgado J. Cardenas A. (2012 ). Expression of antimicrobial peptides in diabetic foot ulcer. J. Dermatol. Sci. 65 19–26.
Not in our library10.1016/j.jdermsci.2011.09.013
153.
Rodriguez C. H. De Ambrosio A. Bajuk M. Spinozzi M. Nastro M. Bombicino K. (2010 ). In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J. Infect. Dev. Ctries. 4 164–167.
Not in our library10.3855/jidc.604
154.
Rogers J. M. Suga H. (2015 ). Discovering functional, non-proteinogenic amino acid containing, peptides using genetic code reprogramming. Org. Biomol. Chem. 13 9353–9363.
Not in our library10.1039/c5ob01336d
155.
Rosenfeld Y. Papo N. Shai Y. (2006 ). Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides: peptide properties and plausible modes of action. J. Biol. Chem. 281 1636–1643.
Not in our library10.1074/jbc.m504327200
156.
Rubinchik E. Dugourd D. Algara T. Pasetka C. Friedland H. D. (2009 ). Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int. J. Antimicrob. Agents 34 457–461.
Not in our library10.1016/j.ijantimicag.2009.05.003
157.
Ryu S. Song P. Seo C. Cheong H. Park Y. (2014 ). Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides. Int. J. Mol. Sci. 15 8753–8772.
Not in our library10.3390/ijms15058753
158.
Sakamoto I. Igarashi M. Kimura K. Takagi A. Miwa T. Koga Y. (2001 ). Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 47 709–710.
Not in our library10.1093/jac/47.5.709
159.
Salmon J. K. Armstrong C. A. Ansel J. C. (1994 ). The skin as an immune organ. West. J. Med. 160 146–152.
Not in our library
160.
Sarma P. Mahendiratta S. Prakash A. Medhi B. (2018 ). Specifically targeted antimicrobial peptides: a new and promising avenue in selective antimicrobial therapy. Indian J. Pharmacol. 50 1–3.
Not in our library10.4103/ijp.ijp_218_18
161.
Schmidtchen A. Pasupuleti M. Malmsten M. (2014 ). Effect of hydrophobic modifications in antimicrobial peptides. Adv. Colloid Interf. Sci. 205 265–274.
Not in our library10.1016/j.cis.2013.06.009
162.
Schneider T. Gries K. Josten M. Wiedemann I. Pelzer S. Labischinski H. (2009 ). The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 53 1610–1618.
Not in our library10.1128/aac.01040-08
163.
Schroder G. Brandenburg K. Seydel U. (1992 ). Polymyxin B induces transient permeability fluctuations in asymmetric planar lipopolysaccharide/phospholipid bilayers. Biochemistry 31 631–638.
Not in our library10.1021/bi00118a001
164.
Schultz H. Weiss J. P. (2007 ). The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin. Chim. Acta 384 12–23.
Not in our library10.1016/j.cca.2007.07.005
165.
Segev-Zarko L. Saar-Dover R. Brumfeld V. Mangoni M. L. Shai Y. (2015 ). Mechanisms of biofilm inhibition and degradation by antimicrobial peptides. Biochem. J. 468 259–270.
Not in our library10.1042/bj20141251
166.
Severina E. Severin A. Tomasz A. (1998 ). Antibacterial efficacy of nisin against multidrug-resistant grampositive pathogens. J. Antimicrob. Chemother. 41 341–347.
Not in our library10.1093/jac/41.3.341
167.
Antimicrobial Nisin Acts Against Saliva Derived Multi-Species Biofilms without Cytotoxicity to Human Oral Cells · 2015
Not checked
168.
Shurko J. F. Galega R. S. Li C. Lee G. C. (2018 ). Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against S. aureus. J. Antibiot. 71 971–974.
Not in our library10.1038/s41429-018-0090-7
169.
Sikora K. Jaśkiewicz M. Neubauer D. Bauer M. Bartoszewska S. Barańska-Rybak W. (2018 ). Counter-ion effect on antistaphylococcal activity and cytotoxicity of selected antimicrobial peptides. Amino Acids 50 609–619.
Not in our library10.1007/s00726-017-2536-9
170.
Sivertsen A. Isaksson J. Leiros H.-K. S. Svenson J. Svendsen J.-S. Brandsdal B. O. (2014 ). Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. BMC Struct. Biol. 14:4.
Not in our library10.1186/1472-6807-14-4
171.
Son D. J. Lee J. W. Lee Y. H. Song H. S. Lee C. K. Hong J. T. (2007 ). Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol. Ther. 115 246–270.
Not in our library10.1016/j.pharmthera.2007.04.004
172.
Sørensen O. E. Thapa D. R. Roupé K. M. Valore E. V. Sjöbring U. Roberts A. A. (2006 ). Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J. Clin. Invest. 116 1878–1885.
Not in our library10.1172/jci28422
173.
Srinivas N. Jetter P. Ueberbacher B. J. Werneburg M. Zerbe K. Steinmann J. (2010 ). Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327 1010–1013.
Not in our library10.1126/science.1182749
174.
Starr C. G. He J. Wimley W. C. (2016 ). Host cell interactions are a significant barrier to the clinical utility of peptide antibiotics. ACS Chem. Biol. 11 3391–3399.
Not in our library10.1021/acschembio.6b00843
175.
Steenbergen J. N. Mohr J. F. Thorne G. M. (2009 ). Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J. Antimicrob. Chemother. 64 1130–1138.
Not in our library10.1093/jac/dkp346
176.
Stevens K. A. Sheldon B. W. Klapes N. A. Klaenhammer T. R. (1991 ). Nisin treatment for inactivation of Salmonella species and other gram-negative bacteria. Appl. Environ. Microbiol. 57 3613–3615.
Not in our library10.1128/aem.57.12.3613-3615.1991
177.
Strömstedt A. A. Pasupuleti M. Schmidtchen A. Malmsten M. (2009 ). Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob. Agents Chemother. 53 593–602.
Not in our library10.1128/aac.00477-08
178.
Taylor S. D. Palmer M. (2016 ). The action mechanism of daptomycin. Bioorganic Med. Chem. 24 6253–6268.
Not in our library10.1016/j.bmc.2016.05.052
179.
Taylor T. M. Gaysinsky S. Davidson P. M. Bruce B. D. Weiss J. (2007 ). Characterization of antimicrobial-bearing liposomes by ζ-potential, vesicle size, and encapsulation efficiency. Food Biophys. 2 1–9.
Not in our library10.1007/s11483-007-9023-x
180.
Tempera G. Mangiafico A. Genovese C. Giudice E. Mastrojeni S. Nicolosi D. (2009 ). In vitro evaluation of the synergistic activity of neomycin-polymyxin b association against pathogens responsible for otitis externa. Int. J. Immunopathol. Pharmacol. 22 299–302.
Not in our library10.1177/039463200902200206
181.
Terwilligert T. C. Eisenbergg D. (1982 ). The structure of Melittin. J. Biol. Chem. 257 6016–6022.
Not in our library
182.
Thwaite J. E. Hibbs S. Titball R. W. Atkins T. P. (2006 ). Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob. Agents Chemother. 50 2316–2322.
Not in our library10.1128/aac.01488-05
183.
Todd P. Pierre K. (2015 ). GlobeNewswire. C3 Jian Complet. Second Phase 2 Clin. Trial Anti-Cavity Drug. Available online at: https://www.globenewswire.com/news-release/2015/07/13/751454/0/en/C3-Jian-Completes-Second-Phase-2-Clinical-Trial-of-Anti-Cavity-Drug.html (accessed September 18, 2020).
Not in our library
184.
Travis S. Yap L. M. Hawkey C. Warren B. Lazarov M. Fong T. (2005 ). RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. 11 713–719.
Not in our library10.1097/01.mib.0000172807.26748.16
185.
Ugurlu T. Turkoglu M. Gurer U. S. Akarsu B. G. (2007 ). Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur. J. Pharm. Biopharm. 67 202–210.
Not in our library10.1016/j.ejpb.2007.01.016
186.
Valencia R. Arroyo L. A. Conde M. Aldana J. M. Torres M.-J. Fernández-Cuenca F. (2009 ). Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30 257–263.
Not in our library10.1086/595977
187.
Van Den Bogaart G. Guzmán J. V. Mika J. T. Poolman B. (2008 ). On the mechanism of pore formation by melittin. J. Biol. Chem. 283 33854–33857.
Not in our library10.1074/jbc.m805171200
188.
Van Epps H. L. (2006 ). René dubos: unearthing antibiotics. J. Exp. Med. 203:259.
Not in our library10.1084/jem.2032fta
189.
Van Groenendael R. Kox M. Van Eijk L. T. Pickkers P. (2018 ). Immunomodulatory and kidney-protective effects of the human chorionic gonadotropin derivate EA-230. Nephron 140 148–151.
Not in our library10.1159/000490772
190.
Wecke T. Zühlke D. Mäder U. Jordan S. Voigt B. Pelzer S. (2009 ). Daptomycin versus friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses. Antimicrob. Agents Chemother. 53 1619–1623.
Not in our library10.1128/aac.01046-08
191.
Welling M. Brouwer C. Roscini L. Cardinali G. Corte L. Casagrande Pierantoni D. (2018 ). Structure-activity relationship study of synthetic variants derived from the highly potent human antimicrobial peptide hLF(1-11). Cohesive J. Microbiol. Infect. Dis.
Not in our library10.31031/cjmi.2018.01.000512
192.
Wimley W. C. Hristova K. (2011 ). Antimicrobial peptides: successes, challenges and unanswered questions. J. Membr. Biol. 239 27–34.
Not in our library10.1007/s00232-011-9343-0
193.
Woong S. J. Xuewei S. L. Sun J. N. Edgerton M. (2008 ). The P-113 fragment of histatin 5 requires a specific peptide sequence for intracellular translocation in Candida albicans, which is independent of cell wall binding. Antimicrob. Agents Chemother. 52 497–504.
Not in our library10.1128/aac.01199-07
194.
Wu C.-L. Hsueh J.-Y. Yip B.-S. Chih Y.-H. Peng K.-L. Cheng J.-W. (2020 ). Antimicrobial peptides display strong synergy with vancomycin against vancomycin-resistant E. faecium, S. aureus, and wild-type E. coli. Int. J. Mol. Sci. 21:4578.
Not in our library10.3390/ijms21134578
195.
Yang C. H. Chen Y. C. Peng S. Y. Tsai A. P. Y. Lee T. J. F. Yen J. H. (2018 ). An engineered arginine-rich α-helical antimicrobial peptide exhibits broad-spectrum bactericidal activity against pathogenic bacteria and reduces bacterial infections in mice. Sci. Rep. 8 1–14.
Not in our library10.1038/s41598-018-32981-3
196.
Mechanism of Action of Surface Immobilized Antimicrobial Peptides Against Pseudomonas aeruginosa · 2020
Not checked
197.
Yasir M. Dutta D. Willcox M. D. P. (2019 ). Mode of action of the antimicrobial peptide Mel4 is independent of Staphylococcus aureus cell membrane permeability. PLoS One 14:e0215703.
Not in our library10.1371/journal.pone.0215703
198.
Yu H. B. Kielczewska A. Rozek A. Takenaka S. Li Y. Thorson L. (2009 ). Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. J. Biol. Chem. 284 36007–36011.
Not in our library10.1074/jbc.c109.073627
199.
Yu K. Lo J. C. Y. Yan M. Yang X. Brooks D. E. Hancock R. E. W. (2017 ). Anti-adhesive antimicrobial peptide coating prevents catheter associated infection in a mouse urinary infection model. Biomaterials 116 69–81.
Not in our library10.1016/j.biomaterials.2016.11.047
200.
Antibacterial Mechanisms of Polymyxin and Bacterial Resistance · 2015
No notice
201.
Zasloff M. (2002 ). Antimicrobial peptides of multicellular organisms. Nature 415 389–395.
Not in our library10.1038/415389a
202.
Zavascki A. P. Goldani L. Z. Li J. Nation R. L. (2007 ). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60 1206–1215.
Not in our library10.1093/jac/dkm357
203.
Zhang J. Zhong J. (2015 ). The journey of nisin development in China, a natural-green food preservative. Protein Cell 6 709–711.
Not in our library10.1007/s13238-015-0214-9
204.
Zhu C. Zhao J. Kempe K. Wilson P. Wang J. Velkov T. (2017 ). A hydrogel-based localized release of colistin for antimicrobial treatment of burn wound infection. Macromol. Biosci. 17:1600320.
Not in our library10.1002/mabi.201600320

Cited by papers we hold 8

Antimicrobial peptides´ immune modulation role in intracellular bacterial infection · 2023
No notice
Antimicrobial Peptide Synergies for Fighting Infectious Diseases · 2023
No notice
Antimicrobial Drug Resistance in Poultry Production: Current Status and Innovative Strategies for Bacterial Control · 2023
No notice
Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides · 2023
No notice
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics · 2022
No notice
Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications · 2022
No notice
Antimicrobial Peptides: A Potent Alternative to Antibiotics · 2021
No notice
Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.